Active, Not Recruiting
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer - CA209-331
Updated: 7 April, 2022 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Histologically or cytologically confirmed small cell lung cancer (SCLC) - Subjects with either limited or extensive disease stage at the initial diagnosis - Must have recurrence or progression after platinum-based first-line chemotherapy or chemoradiation therapy for the treatment of limited or extensive disease stage SCLC - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: - Untreated or symptomatic central nervous system (CNS) metastases - Prior therapy with anti-PD-1, anti-PDL1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody - Inadequate hematologic or hepatic function
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
